These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36574199)

  • 1. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.
    Yale JF; Roborel de Climens A; Aggarwal N; Dex T; Gerstein HC; Harris S; Hramiak I; Stewart J; Leiter LA
    Diabetes Ther; 2023 Feb; 14(2):377-386. PubMed ID: 36574199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
    Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
    Miyoshi H; Matsuhisa M; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Apr; 14(4):671-689. PubMed ID: 36809494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes.
    Pablo Frias J; Lorenz M; Roberts M; Dex T; Schmider W; Hurst W; Skolnik N
    Curr Med Res Opin; 2019 Apr; 35(4):689-695. PubMed ID: 30360647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
    Goldman J; Trujillo JM
    Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
    Skolnik N; Dupree RS; Johnson EL
    Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
    Guja C; Giorgino F; Blonde L; Ali A; Prázný M; Meier JJ; Souhami E; Lubwama R; Ji C; Rosenstock J
    Diabetes Ther; 2022 Jan; 13(1):205-215. PubMed ID: 34894329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes.
    Pohlmeier H; Berard L; Brulle-Wohlhueter C; Wu J; Dahmen R; Nowotny I; Klonoff D
    J Diabetes Sci Technol; 2017 Mar; 11(2):263-269. PubMed ID: 27664062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
    Ferrannini E; Niemoeller E; Dex T; Servera S; Mari A
    Diabetes Obes Metab; 2022 Jun; 24(6):1159-1165. PubMed ID: 35257461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
    Matsuhisa M; Miyoshi H; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Jan; 14(1):219-236. PubMed ID: 36422802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
    Giorgino F; Caruso I; Napoli R
    Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes.
    Hinnen D; Strong J
    Diabetes Spectr; 2018 May; 31(2):145-154. PubMed ID: 29773934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
    Mora PF; Chao J; Saremi A; Dex TA; Roberts M; Umpierrez GE
    Endocr Pract; 2019 Nov; 25(11):1091-1100. PubMed ID: 31241362
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
    Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
    Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
    Schmider W; Belder R; Lee M; Niemoeller E; Souhami E; Frias JP
    Curr Med Res Opin; 2019 Jun; 35(6):1081-1089. PubMed ID: 30550345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
    Kaneto H; Takami A; Spranger R; Amano A; Watanabe D; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():3-13. PubMed ID: 32072742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.
    Inoue M; Lorenz M; Muto H; Wesch R; Hashimoto Y
    Diabetes Obes Metab; 2019 Aug; 21(8):2001-2005. PubMed ID: 31050109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan.
    Yabe D; Matsuhisa M; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2024 Mar; 15(3):705-723. PubMed ID: 38363541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial-Study Design and Protocol.
    Novodvorský P; Thieme L; Laňková I; Mráz M; Taybani ZJ; Bótyik B; Stella P; Vytasil M; Lauand F; Bonnemaire M; Haluzík M
    Diabetes Ther; 2024 Jun; 15(6):1461-1471. PubMed ID: 38653903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.